An FDA approval of MDMA for PTSD would mark a significant step in mainstreaming psychedelics in mental healthcare, while a rejection would be a major setback.
Recent concerns about the validity of MDMA clinical trial results have been raised, potentially jeopardizing the drug's path to approval.
[
add
]
[
|
|
...
]